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Preclinical and clinical studies showed that autologous 
transplantation of epidermis derived from genetically 
modified epithelial stem cells (EpSCs) leads to long-term 
correction of inherited skin adhesion defects. These stud-
ies were based on potentially genotoxic retroviral vectors. 
We developed an alternative gene transfer strategy aimed 
at targeting a “safe harbor” locus, the adeno-associated 
virus integration site 1 (AAVS1), by zinc-finger nuclease 
(ZFN)-induced homologous recombination (HR). Delivery 
of AAVS1-specific ZFNs and a GFP-expressing HR cassette 
by integration-defective lentiviral (LV) vectors (IDLVs) or 
adenoviral (Ad) vectors resulted in targeted gene addi-
tion with an efficiency of >20% in a human keratinocyte 
cell line, >10% in immortalized keratinocytes, and <1% 
in primary keratinocytes. Deep sequencing of the AAVS1 
locus showed that ZFN-induced double-strand breaks are 
mostly repaired by nonhomologous end joining (NHEJ) 
in primary cells, indicating that poor induction of the 
HR-dependent DNA repair pathway may be a significant 
limitation for targeted gene integration. Skin equivalents 
derived from unselected keratinocyte cultures coinfected 
with a GFP-IDLV and a ZFN-Ad vector were grafted 
onto immunodeficient mice. GFP-positive clones were 
observed in all grafts up to 18 weeks post-transplanta-
tion. By histological and molecular analysis, we were able 
to demonstrate highly efficient targeting of the AAVS1 
locus in human repopulating EpSCs.
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INTRODUCTION
Gene replacement therapy for human monogenic diseases has 
shown its therapeutic efficacy in a number of seminal clinical 
studies.1–8 However, the risks related to insertional mutagenesis 
showed the limits of the current integrating gene transfer tech-
nology.9–12 Epidermolysis bullosa (EB) is a family of severe skin 
adhesion genetic defects characterized, in the nonlethal forms, 
by disfiguring blistering, recurrent infections, visual impairment, 
and an increased risk of skin cancer.13–15 There is no cure for 
EB, and current therapies are palliative, aimed at treating infec-
tions and trauma and maintaining an acceptable quality of life. 
Junctional EB is due to autosomal recessive mutations in any of 
the three genes (LAMA2, LAMB3, and LAMG2) encoding the 
laminin 332 heterotrimer. In 2006, we reported the successful 
correction of the skin adhesion defect in a patient affected by 
junctional EB by transplantation of cultured skin derived from 
autologous epithelial stem cells (EpSCs) genetically corrected 
by a Moloney murine leukemia virus-derived retroviral vector 
carrying the LAMB3 cDNA under the control of the viral long-
terminal repeat.16 While the study provided clinical validation for 
the therapeutic potential of this approach, safety concerns were 
raised by the use of a γ-retroviral vector to deliver and express 
the LAMB3 gene. We, therefore, developed and tested a poten-
tially safer, human immunodeficiency virus-derived lentiviral 
(LV) vector in which the LAMB3 cDNA is under the control of 
a keratinocyte-specific enhancer/promoter, and demonstrated 
its efficacy in a preclinical model.17 LV vectors, however, do not 
overcome all the problems associated to uncontrolled integration 
in the human genome,9 and in particular, the post-transcriptional 
deregulation of target endogenous genes by aberrant splicing.9,18,19 
Moreover, they are unsuitable for delivering large genes, such as 
COL7A1, responsible for the dystrophic forms of EB.20,21 Inserting 
LAMB3 or COL7A1 expression cassettes at a precise and prede-
termined location in the genome would overcome the problems 
and limitations associated with the current integrating vectors, 
and increase both the safety and efficacy of EpSC-mediated gene 
therapy.
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To this end, we designed a gene-targeting approach aimed 
at site-specific insertion of a gene into a putative “safe harbor” 
location, the adeno-associated virus integration site 1 (AAVS1) 
locus on chromosome 19, in the genome of human keratinocytes. 
The strategy is based on the use of AAVS1-specific zinc-finger 
nucleases (ZFNs) to induce a targeted double-strand break and 
stimulate a specialized form of homologous recombination (HR) 
known as homology-directed DNA repair. Simultaneous provi-
sion of a suitably designed donor DNA cassette, in which the gene 
of interest is flanked by sequences homologous to the target site, 
results in the site-specific addition of the corrective DNA to the 
targeted site.22–25 The AAVS1 locus allows for robust transgene 
expression without perturbation of the neighboring gene expres-
sion.26–28 ZFNs can be delivered via integration-defective LV vec-
tors (IDLVs),29 AAVs,30 or adenoviral (Ad) vectors,26 which do not 
persist in actively replicating cells. In this study, we provide proof 
of principle that ZFN-mediated, targeted gene addition can be 
achieved in human keratinocytes and in long-term repopulating 
EpSCs in a validated preclinical model of xenotransplantation of 
human skin equivalents on immunodeficient mice.
RESULTS
Targeted gene integration at high efficiency in a 
human keratinocyte cell line
To investigate the feasibility of a ZFN-mediated approach to 
achieve site-specific integration in human keratinocytes, we used 
IDLVs for delivering the ZFNs and an AAVS1-specific HR DNA 
donor template, as previously described.29 Two IDLVs were used to 
deliver a pair of ZFNs designed against intron 1 of the PPP1R12C 
gene (the AAVS1 locus), each carrying a ZFN monomer driven 
by the eukaryotic elongation factor 1α promoter (ZFN-IDLVs). 
A third IDLV carried the donor template, a GFP gene driven by 
the phosphoglycerate kinase promoter and flanked by two 800-bp 
long AAVS1 homology arms (donor-IDLV) (Figure 1a).
We transduced a human keratinocyte cell line (HaCaT) with 
the donor-IDLV either alone or together with increasing doses 
of the two ZFN-IDLVs. Under all conditions tested, we achieved 
up to 70% transduction, as measured 3 days after infection by 
cytofluorimetric analysis of GFP expression (Figure 1b). Twenty-
one days postinfection, the percentage of GFP+ cells decreased 
in all samples, falling to <5% in control cells treated with the 
donor-IDLV alone (4.83 ± 1.09, n = 3) (Figure 1b). By contrast, 
in cells transduced with the ZFN-IDLVs and the donor-IDLV, we 
observed up to 25% (23.9 ± 3.0, n = 3) of the cells retaining GFP 
expression at both doses of ZFN-IDLV vector tested (Figure 1b). 
To confirm that the GFP expression resulted from ZFN-mediated, 
targeted gene addition at the AAVS1 locus, we performed PCR 
analyses on randomly isolated, GFP-expressing individual cell 
clones obtained by limiting dilution of a bulk population infected 
with the donor-IDLV and the ZFN-IDLVs. PCR analyses on 5′ 
and 3′ junctions between the transgene expression cassette and the 
chromosomal AAVS1 locus gave PCR products consistent with 
those expected for precise homology-directed integration events 
in 19 out of 22 HaCaT clones (86%) (Figure 1c). In two clones (#7 
and #15), we were able to amplify only the 3′ junctions, while just 
one clone (#22) scored negative for both the 5′- and 3′- specific 
PCR products, suggesting a bona fide off-target integration event. 
PCR analysis with primers annealing to the primer binding site 
and the Woodchuck hepatitis virus post-transcriptional regula-
tory element in the viral backbone was also performed to detect 
the presence of head-to-tail concatemers of the integration cas-
sette. Twelve out 22 clones (54%) harbored at least two copies of 
the GFP cassette in the target locus (Figure 1c). Sequencing of the 
band of unpredicted size in clone #4 revealed an aberrant duplica-
tion of the Woodchuck hepatitis virus post-transcriptional regula-
tory element and a short fragment of the viral backbone (data not 
shown).
To confirm targeting of the AAVS1 site, genomic DNA was 
also analyzed by Southern blotting. Hybridization with a GFP-
specific probe showed the expected 4.6-kb band in all clones 
analyzed (Figure 2a). An extra band was observed in 4/22 clones 
(18%), most likely the result of additional off-target integra-
tion events (Figure 2a and Supplementary Figure S1). Further 
Southern analysis revealed that 90% of the clones had the GFP 
cassette integrated as either a monomer (65%) or a dimer (35%) in 
the AAVS1 site. In two clones (#20 and #21 in Figure 2b), harbor-
ing three and two copies of the integration cassette, respectively, 
the GFP probe hybridized to a >2-kb extra band indicating an off-
target integration of one copy of the GFP cassette (indicated by 
a star in Figure 2b). Clone #15 revealed a shorter ~8.1-kb band 
which, together with the results of the previous Southern blot 
(Figure 2a) and the PCR analysis (Figure 1b), is consistent with a 
minor truncation (Figure 2b). One clone (#7 in Supplementary 
Figure S2) showed a band of higher than expected size, suggesting 
an off-target integration or most probably a rearrangement at the 
5′ junction of the integrated cassette within the AAVS1 locus, as 
previously detected by PCR analysis (Figure 1c).
Together, these data demonstrate that IDLVs can drive ZFN-
mediated, site-specific gene addition at high frequency and effi-
ciency in a human keratinocyte cell line.
Optimization of ZFN and donor DNA delivery in 
human keratinocytes
Preliminary experiments showed that unlike HaCaT cells, 
human primary keratinocytes grown on a standard feeder layer 
of irradiated NIH3T3-J2 cells are infected at a relatively low effi-
ciency (<15%) by VSV-G-pseudotyped IDLVs (Supplementary 
Figure S3). To improve gene delivery to keratinocytes, we cloned 
the same GFP donor cassette in a first-generation Ad vector 
equipped with a chimeric fiber consisting in the tail of serotype 5 
and the shaft and knob motifs of serotype 50 (Ad5/50). Cells were 
infected with either the donor-IDLV (300 ng of p24) or the donor-
Ad vector at a multiplicity of infection (MOI) varying from 200 
to 1,000, and GFP expression measured 48 hours after infection 
by flow cytometry. Transduction efficiency was at least 2.5-fold 
higher in cells transduced with the donor-Ad vector (35–50%, 
depending on the MOI; Supplementary Figure S3). To determine 
the optimal combination of donor and ZFN vector, we infected 
HaCaT cells with the either the donor-Ad or the donor-IDLV 
together with increasing doses of an Ad5/35 vector, belonging to 
the Adenovirus subgroup B as the Ad5/50 vector, carrying the two 
AAVS1-specific ZFNs driven by a cytomegalovirus promoter and 
linked by a 2A self-cleaving peptide sequence (ZFN-Ad, a kind 
gift of Sangamo Biosciences, Richmond, CA).26 Twelve days after 
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transduction, the culture coinfected with ZFN-Ad and the donor-
IDLV contained 20% GFP+ cells compared with just 1% GFP+ 
cells observed in the culture coinfected with the ZFN-Ad (MOI: 
100–500) and the donor-Ad at MOI 100 (Figure 3a). Increasing 
the donor-Ad MOI over 500 resulted in some cell toxicity without 
any gain in the frequency of stable integration. Nonquantitative 
PCR analysis of the expected 3′ junction between the GFP cassette 
and the chromosomal AAVS1 locus confirmed that HR-mediated 
targeted integration occurred with both types of donor vector, 
although at markedly higher efficiency with the donor-IDLV 
(Figure 3b). The extent of ZFN cleavage at the AAVS1 locus 
repaired by nonhomologous end joining (NHEJ) (% indels) was 
evaluated by Surveyor nuclease (Cel-I) assay on genomic DNA 
from infected cells. We observed increasing % indels in cells 
infected with the ZFN-Ad vector, reaching a maximum of 29% 
at MOI 500 (Figure 3c), suggesting that NHEJ repair is favored 
when the donor cassette is carried by an Ad vector, while HR 
is used at a much higher frequency in the presence of an IDLV 
donor template.
Targeted gene integration in immortalized human EB 
keratinocytes
The efficiency of the donor-IDLV + ZFN-Ad combination in tar-
geting gene integration was then tested in SV40-immortalized 
Figure 1 Targeted gene addition into the adeno-associated virus integration site 1 (AAVS1) locus in human HaCaT keratinocytes. (a) 
Schematic representation of two IDLVs-ZFN, each expressing one ZFN monomer, and the donor IDLV vector; endogenous AAVS1 locus showing the 
ZFNs target site; and targeted integration (TI) of the GFP cassette into AAVS1 locus. (b) HaCaT cells infected with the indicated doses (ng p24) of two 
ZFNs-expressing IDLVs and donor-IDLV. GFP expression was evaluated by flow cytometry 3 and 21 days post-transduction. Data are representative 
of three independent experiments (mean ± SEM; n = 3). (c) PCR analyses on genomic DNA from HaCaT clones derived from the bulk population 
infected at highest dose to determine TI of the GFP expression cassette into the AAVS1 target locus. Two couple of primers specific for the 5′ and 3′ 
integration junctions, amplifying 0.9- and 1.3-kb band, respectively, are indicated by black arrows. The middle panel shows concatemers-specific PCR 
products. The expected bands correspond to 0.7 or 0.9 kb, depending on the presence of one or two long-terminal repeats. The bottom gel shows 
control PCR amplification targeting the GAPDH gene. Bulk: HaCaT infected bulk population. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
IDLV, integration-defective lentiviral vector; PBS, primer binding site; PGK, phosphoglycerate kinase; WPRE, Woodchuck hepatitis virus post-transcrip-
tional regulatory element; ZFN, zinc-finger nuclease.
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primary keratinocytes derived from a patient affected by general-
ized atrophic benign EB (GABEB).31 Unlike HaCaT cells, immor-
talized GABEB keratinocytes showed an almost normal karyotype 
by cytogenetic analysis: >50% of the scored nuclei were diploid 
with minor abnormalities on chromosome 3, 6, 8, 11, 13, 20, and 
X (data not shown). No abnormality was observed in the num-
ber and structure of chromosome 19, hosting the AAVS1 locus. 
Immortalized GABEB keratinocytes were then transduced with 
the donor-IDLV and increasing doses of the ZFN-Ad. We achieved 
>65% transduction efficiency of the donor-IDLV 48 hours postin-
fection under all conditions tested, as analyzed by flow cytometry 
of GFP expression (Figure 4a). Twenty days after infection, we 
observed up to 12.3% GFP+ cells in keratinocytes infected with 
donor-IDLV + ZFN-Ad, compared with 1.3% of GFP+ cells in 
control cultures infected with the donor-IDLV alone (Figure 4a). 
HR-mediated targeted gene addition was confirmed by PCR assays 
specific for the expected 5′ and 3′ junctions between the GFP cas-
sette and the AAVS1 locus (Figure 4b). The Cel-I assay showed 
21–26% indels at the ZFN target site in the AAVS1 locus at all 
three doses of ZFN-Ad vector (MOI: 100, 200, and 500) (Figure 
4c), indicating an almost equal efficiency in HR- versus NHEJ-
mediated DNA repair in the presence of an IDLV donor template 
in immortalized keratinocytes. Increasing the MOI of ZFN-Ad 
>200 did not result in higher cleavage activity but, if anything, in 
a modest decrease of both % indels and % GFP+ cells (Figure 4).
Site-specific gene addition in human primary 
keratinocytes
To assess the efficiency of the donor-IDLV + ZFN-Ad combination 
in targeting integration in primary cells, we infected early passage, 
foreskin-derived human keratinocytes with the donor-IDLV and 
increasing doses of the ZFN-Ad (MOI: 200–1,000). GFP expression 
Figure 2 Molecular characterization of the zinc-finger nuclease-mediated integration events in HaCaT cell clones. (a) Southern blot analysis 
of genomic DNA extracted from HaCaT cell clones, digested with AccI flanking the AAVS1 homology arms, and hybridized to a GFP probe. The 
expected band, corresponding to 4.6 kb, indicates the presence of a GFP expression cassette correctly integrated into the target locus. Clones show-
ing rearrangements or off-target integrations are highlighted by black asterisks. (b) Southern blot analysis of genomic DNA from the same cell clones 
digested with XbaI, single cutter in the donor cassette, and hybridized to a GFP probe. A band corresponding to 8.3 kb indicates integration of one 
copy of the GFP expression cassette into the AAVS1 target locus. A band higher than 2 kb indicates random integration of one copy of the GFP cas-
sette (black asterisks). Finally, a 5.8-kb band indicates the presence of integrated head-to-tail vector concatemers. The first lane on the left-hand side 
of each Southern blot corresponds to the molecular weight marker. AAVS1, adeno-associated virus integration site 1; NTC, nontreated cells; PGK, 
phosphoglycerate kinase; RRE, rev-responsive element; WPRE, Woodchuck hepatitis virus post-transcriptional regulatory element.
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analysis revealed a transduction efficiency of 14–20% 48 hours 
postinfection in all conditions, confirming the low transduction 
efficiency by IDLVs in primary keratinocytes. Fourteen days after 
infection, the number of GFP+ cells decreased to 0.3% in cultures 
infected with donor-IDLV + ZFN-Ad (0.27 ± 0.03, n = 3), and below 
0.1% in cells infected with the donor-IDLV alone (Figure 5a). PCR 
analysis of the 5′ and 3′ junctions between the GFP cassette and 
the AAVS1 locus showed HR-mediated targeted integration in the 
bulk population of primary keratinocytes (Figure 5b), which was 
confirmed by sequencing both ends of the PCR products (data not 
shown). Cel-I assay carried out 48 hours postinfection revealed 
4, 7, and 9% indels in the AAVS1 alleles in keratinocytes infected 
with the ZFN-Ad at MOIs of 200, 500, and 1,000, respectively 
(Figure 5c), indicating a 10- to 30-fold lower efficiency of HR- ver-
sus NHEJ-mediated repair in these cells (a summary of the relative 
efficiency of HR- and NHEJ-mediated gene repair in all tested cell 
types is reported in Supplementary Table S1).
Deep sequencing of the AAVS1 target site in primary kerati-
nocytes infected with the ZFN-Ad vector at MOI 500 allowed the 
identification of the types of indels introduced by NHEJ repair. 
More than 99% of the sequences retrieved from uninfected cells 
(7,538 out of 7,548) perfectly matched the AAVS1 sequence 
(UCSC hg19 release of the human genome). Alignment of the 
14,195 sequences retrieved from cells infected with ZFN-Ad iden-
tified 1,214 sequences (8.5% of the reads, P < 2.2 × 10–16) carry-
ing insertions and/or deletions within a 90-bp window (−45 to 
+45) around the 6-bp spacer of the ZFN target site. In particu-
lar, 624 sequences contained deletions of 1–45 bp, and predomi-
nantly of 1 bp (17.7% of sequences), 2 bp (6.7%), 4 bp (3.9%), and 
10 bp (5.5%), while 559 sequences contained insertions ranging 
from 1 to 20 bp and predominantly (>93%) <4 bp. Twenty-nine 
sequences (2.4%) contained insertions and deletions of at least 
1 bp. By restricting the analysis to a 24-bp window around the 
ZFN target site, we observed that 64% (776) of the 1,214 mutated 
sequences were clustered in the ZFN binding sites, with 424 
sequences containing 1- to 25-bp deletions, 338 sequences con-
taining 1- to 13-bp insertions, and 14 sequences containing inser-
tions and deletions of at least 1 bp.
Figure 3 ZFN-Ad delivery in HaCaT cells. (a) HaCaT cells were infected 
with the indicated doses of ZFN-Ad (MOI) and donor-IDLV (ng p24) or 
Ad donor (MOI) and analyzed by fluorescence-activated cell sorting for 
GFP expression 3 and 12 days after transduction. (b) AAVS1-targeted 
PCR on genomic DNA isolated from HaCaT bulk populations 12 days 
after infection using primers specific for the 3′ integration junction 
amplifying a 1.7-kb band. (c) Cel-I assay on HaCaT cells infected with 
ZFN-Ad (MOI: 100, 200, and 500). The PCR product spanning the ZFN 
target site was loaded before and after nuclease treatment. Frequencies 
of gene disruption are indicated as % indels. Ad, adenoviral; IDLV, inte-
gration-defective lentiviral vector; MOI, multiplicity of infection; ZFN, 
zinc-finger nuclease.
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Figure 4 Targeted integration in immortalized generalized atrophic 
benign epidermolysis bullosa (GABEB) keratinocytes. (a) Analysis of 
GFP expression 48 hours and 20 days after infection with donor-IDLV 
and ZFN-Ad. (b) PCR analysis of the 5′ and 3′ junction between the 
expression cassette and the adeno-associated virus integration site 1 
locus. C, GFP+ HaCaT clone used as a positive control. (c) Cel-I assay 
performed on immortalized GABEB cells infected with MOI 100, 200, or 
500 of ZFN-Ad vector, as described for HaCaT cells. % Indels: frequency 
of insertions–deletions. Ad, adenoviral; IDLV, integration-defective lenti-
viral vector; MOI, multiplicity of infection; NTC, nontreated cells; ZFN, 
zinc-finger nuclease.
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To assess cell toxicity associated to ZFN-Ad infection in 
human primary keratinocytes, we measured the induction of 
apoptosis 48 hours after infection by flow cytometry after Annexin 
V-PE staining. In both uninfected and ZFN-Ad–infected primary 
keratinocytes, the percentage of apoptotic cells was ~1.5%, inde-
pendently from the MOI (200–1,000). A slightly higher level of 
apoptotic cells (2.3–3.5%) was observed in the control, GFP-Ad–
infected cells. To look at the effect of IDLV + ZFN-Ad combined 
infection on proliferation and colony forming efficiency (CFE) 
of clonogenic keratinocyte progenitors, we infected keratinocyte 
cultures with the donor-IDLV and the ZFN-Ad vector at MOI 
200 and 500, and determined the number of cells and CFE at dif-
ferent time points. The cell proliferation assay showed a slightly 
reduced number of cells 72 hours postinfection (T1) but not at 
later time points (Supplementary Figure S4). A CFE assay was 
carried out at passage T0 (uninfected cells) up to T5 after infec-
tion, corresponding to 32 days of culture. No significant difference 
was observed at any time point between control uninfected and 
infected keratinocytes (Supplementary Figure S5). These results 
indicate that coinfection with donor-IDLV + ZFN-Ad does not 
affect proliferation and clonogenic efficiency of human keratino-
cytes in vitro, and has no significant toxic effect on keratinocyte 
progenitors.
ZFN-mediated targeted gene addition in human 
repopulating keratinocyte stem cells
To determine the efficiency of targeted gene addition in kerati-
nocyte stem cells, we used an in vivo assay measuring the long-
term engrafting potential of genetically modified EpSCs upon 
xenotransplantation on immunodeficient (nu/nu) mice. In this 
assay, skin equivalents are grown ex vivo by seeding keratino-
cytes on a dermal equivalent composed of a fibroblast-containing 
fibrin matrix and grafted on the dorsal region of immunodefi-
cient mice, as previously described.32,33 Human primary kerati-
nocytes were infected with donor-IDLV + ZFN-Ad (MOI: 500) 
as described above. One week after infection, the cultures con-
tained 3–8% of GFP+ cells, and were plated on fibrin matrix to 
prepare 10 transplantable human skin equivalents to be grafted 
on the back of 10 nu/nu immunodeficient mice. Eight out of 10 
mice that received the genetically modified skin equivalents were 
successfully grafted, an expected efficiency for this type of assay, 
indicating that the combined vector infection did not affect the 
in vivo regeneration capacity of EpSCs. The grafts were ana-
lyzed macroscopically, histologically, and molecularly 8 and 18 
weeks after transplantation. Epifluorescent illumination of the 
transplanted zone allowed in vivo monitoring of the genetically 
modified graft up to 18 weeks after grafting. Five out of eight suc-
cessfully grafted mice showed GFP+ spots 8 weeks after trans-
plantation, indicating that the GFP transgene cassette had been 
stably integrated into transplantable clonogenic cells. Seven GFP+ 
skin biopsies (1.1, 1.2, 2, 3.1, 3.2, 4.1, and 5) were obtained from 
five independent grafts representative of five mice (#1–5) 8 weeks 
post- transplantation, and two more GFP+ spots (4.2 and 4.3) were 
obtained from the same graft (mouse #4) 18 weeks post-trans-
plantation. The skin biopsies were sectioned and analyzed for GFP 
expression by fluorescence microscopy. In all cases, we observed 
columns of GFP+ cells extending from the basal cell layer to the 
surface of the graft, indicating engraftment of basal layer stem/
progenitor cells expressing the transgene throughout terminal 
differentiation (Figure  6a). Molecular analysis performed on 
genomic DNA extracted from all nine biopsies showed the pres-
ence of the GFP transgene by PCR analysis (Figure 6b). Seven out 
of nine biopsies (1.1,1.2, 3.1, 3.2, 4.1, 4.2, and 4.3) showed the PCR 
products expected for HR-mediated 5′ and 3′ AAVS1-transgene 
junctions (Figure 6b). The correct, site-specific genomic inser-
tion was confirmed by DNA sequencing in at least one, randomly 
selected amplified junction (Supplementary Figure S6a). The 
remaining two biopsies (2 and 5) resulted positive only for the 5′ 
Figure 5 Targeted gene addition in adeno-associated virus integra-
tion site 1 (AAVS1) locus in human primary keratinocytes. (a) Human 
primary keratinocytes were infected with the indicated doses of ZFN-Ad 
(MOI: 200, 500, and 1000) and donor-IDLV (ng p24). The GFP expres-
sion was evaluated by fluorescence-activated cell sorting analysis 48 
hours and 14 days after transduction. Data are representative of three 
independent experiments (mean ± SEM; n = 3). (b) PCR analyses on the 
5′ and 3′ junction between the integrated cassette and the AAVS1 locus, 
as performed on HaCaT cells. C, HaCaT GFP+ clone as a positive control. 
(c) Cel-I assay on genomic DNA of HaCaT and immortalized general-
ized atrophic benign epidermolysis bullosa cells isolated 48 hours after 
infection with increasing doses (MOI) of ZFN-Ad. % Indels: frequency of 
insertion or deletions. Ad, adenoviral; IDLV, integration-defective lenti-
viral vector; MOI, multiplicity of infection; NTC, nontreated cells; ZFN, 
zinc-finger nuclease.
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AAVS1-transgene junctions (Figure 6b). To validate the positive 
signal of those junctions, we sequenced the PCR products. The 
sequences demonstrated a genuine genome-expression cassette 
junction (Supplementary Figure S6b,c).
Taken together, these data indicate that transduction of 
human keratinocyte cultures with the ZFN-Ad and an AAVS1-
IDLV vector induces targeted gene addition, at low frequency but 
with remarkable precision, in EpSCs able to maintain a skin graft 
for up to 18 weeks.
DISCUSSION
Integration of a therapeutic transgene at a precise location into 
the human genome is a major goal in the development of new 
gene transfer technology. A number of gene therapy applications, 
such as transplantation of genetically modified somatic stem cells, 
require permanent expression of the therapeutic gene, and thus 
stable genomic integration of the transgene expression cassette. 
Retroviral vectors have been the only clinically applicable inte-
grating technology for almost 20 years. It is becoming obvious, 
however, that the uncontrolled insertion of a transgene expression 
cassette mediated by γ-retroviral or LV vectors may severely inter-
fere with genetic and epigenetic mechanisms of gene regulation at 
both transcriptional and post-transcriptional levels, and lead to 
harmful genotoxic consequences in patients.34 There are several 
possible solutions to this problem, which range from improving 
the current retroviral vector design to developing entirely new 
technology. An attractive possibility is the design of new vectors 
aimed at driving transgene addition into “safe” genomic loci in 
the human genome. The preferred integration site of AAV on 
human chromosome 19, the AAVS1 locus, represents one such 
putative site. Originally, attempts to target AAVS1 employed the 
AAV Rep replicase-integrase to drive site-specific integration.35–37 
More recently, ZFN technology has been used to mediate HR at 
this site.26,38
In this study, we have investigated the feasibility of a ZFN-
mediated approach to achieve AAVS1-specific integration of a 
GFP reporter gene in the genome of human keratinocytes and 
EpSCs with in vivo repopulating activity. We have described two 
delivery platforms. The first is entirely based on IDLVs, two of 
which carry ZFNs designed to introduce a double-strand break 
in the first intron of the PPP1R12C gene (the AAVS1 locus), and a 
third carrying a GFP expression cassette flanked by AAVS1 homol-
ogy arms. The second platform is based on a first-generation Ad 
vector expressing both AAVS1-specific ZFNs, and the donor cas-
sette again provided by an IDLV vector. Under both conditions, 
we achieved >20% stable integration of the donor GFP cassette 
in the human keratinocyte cell line HaCaT, and >10% in SV40-
immortalized keratinocytes from a GABEB patient. Molecular 
analyses on isolated HaCaT clones showed that almost 90% of 
the integration events were mediated by homology-directed 
repair. Unfortunately, our attempts to increase the frequency of 
HR-mediated integration by delivering also the donor integration 
cassette by an Ad vector failed, as the Ad DNA genome appar-
ently provided a much less efficient HR template compared with 
the IDLV carrying the same donor cassette. Both Ad and LV vec-
tor genomes have a mostly linear, double-stranded conformation 
in cell nuclei, and it is, therefore, difficult to understand why an 
IDLV would be superior to an Ad genome as an HR template. 
One possibility is that a LV preintegration complex is capable of 
actively recruiting the HR-mediated DNA repair complex as part 
of its integration process, may be during the strand invasion step, 
thus facilitating HR-mediated integration of an LV genome asso-
ciated to a defective human immunodeficiency virus integrase. 
The inefficiency of the Ad genome to serve as a donor template is 
unfortunate: large-capacity Ad genomes would be ideal for deliv-
ering large payloads to keratinocytes, such as a COL7A1 expres-
sion cassette necessary for gene therapy of recessive dystrophic 
EB. Additional studies are, therefore, required to optimize the 
conformation of the template and the cofactors involved in medi-
ating HR from an Ad-encoded donor template.
Encouraged by the results obtained in cell lines, we investigated 
the feasibility of using the ZFN-mediated approach to insert a gene 
expression cassette in primary keratinocytes, keratinocyte progeni-
tors, and EpSCs. Targeted integration occurred in vitro in <1% of 
transduced, unselected keratinocytes, a much lower efficiency 
compared with HaCaT cells or SV40-immortalized keratinocytes, 
even considering the overall lower transient transduction efficiency 
Figure 6 Transplantation of engineered human primary keratino-
cyte onto immunodeficient mice. (a) Representation of one mouse 
engrafted with human keratinocytes transduced with zinc-finger nucle-
ase-Ad and integration-defective lentiviral vector donor and examined 
8 and 18 weeks post-transplant (p.t.), and GFP expression monitored 
in vivo under an ultraviolet lamp is shown. Fluorescence analysis of GFP-
expressing cells was performed in histological cryosections from single 
GFP-positive spots of regenerated epidermis. (b) PCR analyses on nine 
biopsies (1.1, 1.2, 2, 3.1, 3.2, 4.1, 4.2, 4.3, and 5) harvested from five 
treated mice (1–5) 8 and 18 weeks after grafting. GFP-specific PCR 
shows the correct 0.5-kb amplified fragment. 5′ TI and 3′ TI indicate the 
5′ and 3′ GFP cassette-genome junctions. At bottom, control PCR ampli-
fication targeting the GAPDH gene is shown. The size of the expected 
bands is indicated on the left. C, HaCaT clone carrying a single copy of 
GFP expression cassette integrated into adeno-associated virus integra-
tion site 1 target locus. GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; Hu, human skin; Mu, murine skin; NTC, nontreated cells; TI, 
targeted integration.
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obtained with the ZFN-Ad + donor-IDLV combination in primary 
cells. Comparing the efficiency of ZFN-mediated double-stranded 
DNA cleavage, analyzed by both a gel mobility assay and deep 
sequencing of the AAVS1 locus, we observed that in HaCaT cells, 
the majority of the cleaved DNA is repaired by HR with the incorpo-
ration of the donor cassette, whereas in primary keratinocytes, HR 
occurs with a frequency 30-fold lower than NHEJ, apparently the 
preferred mechanism for repairing ZFN-induced double-stranded 
breaks. These data suggest that the major limitation of ZFN-mediated 
targeted integration in primary cells is not a reduced cleavage activity 
of the ZFNs but rather a failure to activate the HR pathway to repair 
DNA. Interestingly, the efficiency of homology-directed DNA repair 
in SV40-immortalized keratinocytes is somewhat intermediate 
between HaCaT and primary cells with almost 50% of the double-
stranded break repaired by HR-mediated mechanisms. Apparently, 
immortalization somehow activates the HR pathway may be as a 
consequence of the altered cell cycle progression, thus resulting in 
significant level of ZFN-mediated targeted integration (>10%).
Despite the overall poor efficiency obtained in primary kera-
tinocytes, we decided to test the efficiency of targeted gene deliv-
ery in EpSCs, defined by their ability to maintain stable human 
skin xenografts on immunodeficient mice for more than 8 weeks. 
EpSCs are relatively abundant in a primary keratinocyte culture, 
and can be cloned, tested for site-specific integration, selected, 
and expanded before transplantation, as previously demonstrated 
with retrovirus-transduced human keratinocytes.33 To demon-
strate HR-mediated gene addition in EpSCs, we transplanted skin 
equivalents derived from keratinocyte cultures cotransduced with 
donor-IDLV and ZFN-Ad on nu/nu mice, without selecting for 
GFP-positive cells. In situ analysis of the transplanted skin and 
histological and molecular analysis confirmed that HR-mediated 
integration occurred in long-term repopulating, bona fide stem 
cells. Although the in vivo assay cannot be considered quantitative, 
it clearly demonstrated that the efficiency of targeted integration 
is similar in keratinocytes in vitro and clonogenic EpSCs in vivo, 
and that the major limitation of the ZFN-mediated approach is 
the lack of efficient engagement of the HR-mediated DNA repair 
pathway. Previous studies clearly showed similar difficulties in 
targeting the CCR5 or the AAVS1 locus in human hematopoietic 
stem/progenitor cells compared with established hematopoietic 
cell lines,26,29 suggesting that human stem cells might be generally 
difficult to engineer by ZFN-based technology unless strategies 
are found to induce HR-mediated DNA repair more efficiently. 
Nonetheless, our study shows that gene targeting in transplant-
able somatic stem cells is feasible and lead to stable, site-specific 
gene addition in their progeny. These results open some hopes for 
the development of a “gene correction” approach to gene therapy 
for skin adhesion defects, where rare corrected stem cells can be 
isolated by cloning and used to derive corrected skin implants.
MATERIALS AND METHODS
Vectors and ZFNs. The IDLV containing the donor GFP cassette and the 
AAVS1-specific ZFNs have been described previously.28 The Ad vector 
containing the AAVS1-specific ZFN expression cassettes was previously 
described.26,39 The Ad donor vector was obtained by cloning the phospho-
glycerate kinase. GFP expression cassette flanked by sequences homologous 
for the AAVS1 locus into a pShuttle vector (Stratagene, La Jolla, CA). Given 
the higher capacity of the Ad vector compared with that of the LV vector, 
the homologous regions were extended in the former by including nucleo-
tide from 670 through 2,183 of the AAVS1 locus for the arm upstream of 
the expression cassette and from nucleotide 2,190 through 3,386 for the 
arm downstream of the expression cassette. The shuttle vector was then 
recombined in BJ5183 competent cells with an AdEasy-based backbone 
encoding chimeric 5/50 fibers, resulting in the assembly of molecular clones 
containing the first-generation Ad5/50 genome. Next, these clones were 
treated with PacI enzyme and subsequently transfected by using ExGen 500 
(Fisher Scientific, The Netherlands) into Ad serotype 5 early region 1 (E1)-
complementing PER.C6 cells. The resulting rescued vector particles were 
propagated in PER.C6 cells, after which they were purified through CsCl 
density gradient ultracentrifugation. The viral vector titer was determined 
via 50% tissue culture infectious dose assay in E1-complementing 911 cells.
Cell culture. Human HaCaT cells were maintained in Dulbecco’s modified 
Eagle’s medium (Lonza, Basel, Switzerland) supplemented with 10% fetal 
bovine serum (Lonza). Clones were obtained by limiting dilution, plating the 
cells in 96-well plates at a concentration of 0.3 cells/well. Keratinocytes from 
homozygous GABEB patients immortalized with SV40 (kindly provided 
by Johann W. Bauer) were cultivated in Epilife medium supplemented with 
human keratinocyte growth supplement (Invitrogen, Milan, Italy). Epilife is 
a serum-free keratinocyte culture medium with a low calcium (0.06 mmol/l) 
concentration supplemented with human keratinocyte growth supplement 
which results in a final concentration of 0.2% (vol/vol) bovine pituitary 
extract, 5 µg/ml bovine insulin, 0.18 µg/ml hydrocortisone, 5 µg/ml bovine 
transferrin, and 0.2 ng/ml human epidermal growth factor. Swiss mouse 
3T3-J2 cells (a kind gift from Yan Barrandon, EPFL, Lausanne, Switzerland) 
were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% 
donor bovine serum (GIBCO, Milan, Italy), 50 IU/ml penicillin–streptomy-
cin, and 4 mmol/l glutamine. Primary human keratinocytes from foreskin 
biopsy were plated onto lethally irradiated 3T3-J2 cells and cultured in kera-
tinocyte growth cFAD medium, a Dulbecco’s modified Eagle’s medium and 
Ham’s F12 media mixture (3:1) containing fetal bovine serum (10%), peni-
cillin–streptomycin (1%), glutamine (2%), insulin (5 µg/ml), adenine (0.18 
mmol/l), hydrocortisone (0.4 µg/ml), cholera toxin (0.1 nmol/l), and triiodo-
thyronine (2 nmol/l). After 3 days, epidermal growth factor at a concentra-
tion of 10 ng/ml was added to the culture. Keratinocytes were trypsinized at 
subconfluency and replated onto a new feeder layer.
A CFE assay on treated and untreated keratinocytes cultured for 
4–5 weeks was performed as follows. At each passage, 5 × 102–4 × 103 
keratinocytes (untreated, donor-IDLV, or donor-IDLV/ZFN-Ad–treated 
cells) were plated in a 100-mm culture dish onto lethally irradiated 3T3-
J2 cells and cultured in keratinocyte growth cFAD medium; epidermal 
growth factor (10 ng/ml) was added in the first medium change. Cultures 
were maintained at 37 °C, 5 % CO2 for 12 days and fed three times 
weekly. After that time, culture medium was discarded and stained 
with Rhodamine B solution at 2% (formaldehyde 37% diluted 1:10 and 
Rhodamine B) for 24 hours; then Rhodamine B was discarded and 
washed with water. The CFE was calculated as follows: % CFE = (grown 
colonies/seeded cells) × 100.
Among the colonies, we counted specifically the abortive colonies and 
we calculated the % abortive colonies as follows: % abortive colonies = 
(number of abortive colonies/number of grown colonies) × 100.
Transduction of keratinocytes. HaCaT cells (1 × 105) and immortalized 
GABEB cells (2.5 × 105) were seeded in 6-well plates and infected by spin-
oculation (one round at 1,800 rpm for 45 minutes) with 200 ng p24 of donor 
IDLV and/or 50 and 100 ng p24 of each IDLV-ZFN. Ad transduction was 
performed in serum-free medium containing the viral particles at MOIs 100, 
200, or 500 in the presence of polybrene (8 µg/ml). After 1 hour at 37 °C, 
the transduction mixture was replaced with regular medium. In the samples 
treated with the donor-IDLV/ZFN-Ad platform, infection with Ad vector 
always followed infection with LV vector. Human primary keratinocytes were 
seeded onto 3T3-J2 feeder cells and infected after 16 hours under the same 
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conditions used for the cell lines. Infected cells were grown for at least 14 days 
to avoid scoring GFP expression from unintegrated vector. Transduction 
efficiency was evaluated at different time points by flow cytometry for GFP 
expression (FACS Canto II; Becton Dickinson/Pharmingen, Milan, Italy). 
For apoptosis analysis, Annexin V (Becton Dickinson) was added to 1 × 105 
cells at 48 hours after transduction and analyzed by fluorescence-activated 
cell sorting according to the manufacturer’s instruction.
Targeted integration analysis. Genomic DNA was isolated with either 
Blood & Cell Culture DNA Mini or Micro Kit (Qiagen, Milan, Italy). Briefly, 
100 and 500 ng of genomic DNA from HaCaT cells and primary kerati-
nocytes, respectively, was subjected to PCR (PCR GoTaq; Promega, Milan, 
Italy) using primers TI5 and TI3 and the following conditions: 95 °C for 
5 minutes, then 30 cycles of 95 °C for 30 seconds, 61 °C for 45 seconds, 
72 °C for 30 seconds, followed by 72 °C for 7 minutes. When using the 
Ad5/50 donor vector, targeted integration was assessed only at the 3′ junc-
tion with a primer specific for a region in AAVS1 outside the larger homol-
ogy sequence present in the vector (TI3Ad primer). To detect the presence 
of integrated concatemers, 100 ng genomic DNA was PCR amplified using 
specific primers and the following cycling conditions: 95 °C for 5 minutes, 
then 30 cycles of 95 °C for 30 seconds, 61 °C for 45 seconds, 72 °C for 30 
seconds, followed by 72 °C for 7 minutes. PCR amplicons were resolved on 
1% agarose gel and visualized by ethidium bromide staining. All primers 
are listed in the Supplementary Table S2. For Southern blot analyses, 10 µg 
of genomic DNA was digested overnight with AccI or XbaI, run on a 0.8% 
agarose gel, transferred to a nylon membrane (Hybond-XL; Amersham, 
Milan, Italy), and probed with 2 × 107 cpm 32P-labeled GFP probe.
Cel-I (Surveyor nuclease) assay. Genomic DNA was extracted with the 
Blood & Cell Culture DNA Mini Kit (QIAGEN) according to manufactur-
er’s instructions. Frequency of gene modification by NHEJ was evaluated by 
Surveyor endonuclease assay (Cel-I; Transgenomics, Glasgow, UK) accord-
ing to manufacturer’s instructions. Briefly, the genomic DNA purified from 
ZFN-Ad–infected keratinocytes was used as a template to amplify a short 
region of the AAVS1 site flanking the ZFN target site using the specific prim-
ers Cel-1F and Cel-1R (Supplementary Table S2) and the following condi-
tions (Taq High Fidelity; Invitrogen): 95 °C for 5 minutes, then 40 cycles of 95 
°C for 30 seconds, 61 °C for 30 seconds, and 68 °C for 30 seconds. As control, 
genomic DNA purified from uninfected human keratinocytes was subjected 
to PCR amplification using the same conditions. The PCR products were 
then heated, allowed to reanneal followed by a treatment with the nucleotide 
mismatch-sensitive Surveyor nuclease40 in order to detect insertions and dele-
tions caused by NHEJ. The percentage of indels was calculated by densitomet-
ric analysis comparing between digested with undigested amplicons.
454 Deep sequencing. Genomic DNA was isolated from ZFN-Ad–
infected and uninfected keratinocytes using the QIAamp DNA 
Micro Kit (Qiagen). A 500 ng genomic DNA was then PCR ampli-
fied using Platinum Taq High Fidelity (Invitrogen) using primers HS 
(Supplementary Table S2) joint to 454 adaptor sequences (forward 
5′-CTATGCGCCTTGCCAGCCCGCTCAG-3′, reverse 5′-CGTATCGCC 
TCCCTCGCGCCATCAG-3′) and four nucleotides. DNA barcodes to 
discriminate between untreated (barcode: TAGC) and treated (barcode: 
CGTA) cells. The cycling conditions were 95 °C for 5 minutes, then 20 
cycles of 95 °C for 30 seconds, 55 °C for 3 seconds, 68 °C for 30 seconds; 
1/50 of the product was then subjected to a second round of amplification 
using the same conditions. Following PCR amplification, the PCR prod-
uct was analyzed on a 1% agarose gel, extracted and then purified using 
QIAquick Gel extraction kit (QIAGEN). DNA samples were then pooled 
at a molar ratio of 1:3 favoring the infected cells and run on a Roche/454 
GS FLX using titanium chemistries by GATC Biotech AG Next Gen Lab 
(Konstanz, Germany). Approximately, 25,000 reads were obtained for both 
amplicons. Sequences derived from ZFN-Ad–infected and uninfected cells 
were separated thanks to their different barcode. Any reads containing 
ambiguous base calls or without a perfect match to barcode and primer 
were discarded. The reference sequence was assembled using reads from 
both ZFN-Ad–infected and uninfected cells assembled and the software 
Newbler (version 2.6). The resulting contigs were searched against the ref-
erence sequence of Hg19 with BLASTN to verify the percentage of identity 
between reference target and contigs. Contigs that matched with the best 
similarity were further used as reference to map reads from ZFN-Ad–
infected and uninfected cells using gsMapper (version 2.6). Deviations 
from the AAVS1 consensus sequence were quantified using ad-hoc R 
scripts. All deviations (deletions and insertions) from AAVS1 consensus 
sequence were determined considering 45 and 12 bp up- or downstream 
from the ZFN binding site, respectively.
Bioengineered skin preparation and grafting to immunodeficient mice. 
The bioengineered human skin equivalent is based on the use of a fibrin 
matrix containing live fibroblasts as a dermal component.32 Briefly, 3 ml of 
fibrinogen (from swine plasma cryoprecipitates) were added to 12 ml of 
Dulbecco’s modified Eagle’s medium with 10% fetal calf serum contain-
ing 5 × 105 dermal fibroblasts and 500 IU of bovine aprotinin (Trasylol; 
Bayer, West Haven, CT). Immediately afterwards, 1 ml of 0.025 mmol/l 
CaCl2 (Sigma, St Louis, MO) containing 11 IU of bovine thrombin (Sigma) 
were added. Finally, the mixture was distributed on a 6-well culture plate 
(Transwell; Costar, Cambridge, MA) and allowed to clot at 37 °C for 2 
hours. Human keratinocytes, including those genetically modified (5 × 105 
per well in 3 ml of keratinocyte medium), were then seeded on top of the 
dermal equivalents and allow to grow to confluence. Graft recipient mice 
were aseptically cleansed and grafted with bioengineered skin equiva-
lents as previously described.17,41 Briefly, full-thickness 35-mm circular 
wounds were created on the dorsum of the 6-week old female nu/nu mice 
(Janvier Labs, Saint Berthevin, France). Bioengineered skin equivalents 
were manually detached from the wells and placed orthotopically on the 
wound and covered with freeze-thawed (three cycles) devitalized mouse 
skin. Regenerated human skin became visible, upon mouse devitalized 
skin spontaneously detached, 3–4 weeks after grafting. Mice were housed 
for the duration of the experiment at the CIEMAT Laboratory Animals 
Facility (Spanish registration number: 28079-21 A) in pathogen-free con-
ditions using individually ventilated type II cages (25 air changes per hour) 
and 10 kGy-irradiated soft wood pellets as bedding.
In vivo skin analysis and sampling. Surviving individual mice with suc-
cessful engraftment (n = 8) were analyzed at different time points post-
grafting. The presence of GFP-positive epidermal spots within engrafted 
human skins was determined with a stereomicroscope equipped with a 
GFP illumination source and filters. GFP fluorescent spots were carefully 
excised either as biopsies (taken with a 2-mm skin biopsy punch) on anes-
thetized mice or after sacrifice. Samples were either fixed in 4% buffered 
paraformaldehyde (pH 7.4) for 40 minutes at 4 °C, equilibrated in 30% 
sucrose in primer binding site overnight for GFP analysis on frozen sec-
tions or snap frozen for molecular analysis.
SUPPLEMENTARY MATERIAL
Figure S1. Southern blot analysis of HaCaT cell clones digested with 
AccI.
Figure S2. Southern blot analysis of HaCaT cell clones digested with 
XbaI.
Figure S3. Transduction efficiency of IDLV and Ad vector in human 
primary keratinocytes.
Figure S4. Cell proliferation assay on keratinocytes untreated and 
infected with IDLV donor alone or together with the ZFN-Ad vector.
Figure S5. Colony forming efficiency assay on keratinocytes untreat-
ed and infected with IDLV donor alone or together with the ZFN-Ad 
vector.
Figure S6. Sequence of 5′ and 3′ TI junctions in mouse biopsies.
Table S1. Comparison between cleavage efficiency (% indels) and 
percentage of GFP integration in the cell types tested.
Table S2. List of primers used for targeted integration analyses.
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